Non-Small Cell Lung Cancer - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 2029
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: NA28E2E58C0EN
Leaflet:

Download PDF Leaflet

Non-Small Cell Lung Cancer - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Non-Small Cell Lung Cancer - Pipeline Review, H2 2015’, provides an overview of the Non-Small Cell Lung Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Non-Small Cell Lung Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Non-Small Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Non-Small Cell Lung Cancer Overview
Therapeutics Development
Non-Small Cell Lung Cancer - Therapeutics under Development by Companies
Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes
Non-Small Cell Lung Cancer - Pipeline Products Glance
Non-Small Cell Lung Cancer - Products under Development by Companies
Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes
Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development
Non-Small Cell Lung Cancer - Therapeutics Assessment
Drug Profiles
Non-Small Cell Lung Cancer - Recent Pipeline Updates 1323
Non-Small Cell Lung Cancer - Dormant Projects 1927
Non-Small Cell Lung Cancer - Discontinued Products 1954
Non-Small Cell Lung Cancer - Product Development Milestones 1965
Appendix 1975

LIST OF TABLES

Number of Products under Development for Non-Small Cell Lung Cancer, H2 2015
Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Development by Companies, H2 2015 (Contd..10)
Number of Products under Development by Companies, H2 2015 (Contd..11)
Number of Products under Development by Companies, H2 2015 (Contd..12)
Number of Products under Development by Companies, H2 2015 (Contd..13)
Number of Products under Development by Companies, H2 2015 (Contd..14)
Number of Products under Development by Companies, H2 2015 (Contd..15)
Number of Products under Development by Companies, H2 2015 (Contd..16)
Number of Products under Development by Companies, H2 2015 (Contd..17)
Number of Products under Development by Companies, H2 2015 (Contd..18)
Number of Products under Development by Companies, H2 2015 (Contd..19)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Development by Companies, H2 2015 (Contd..14)
Products under Development by Companies, H2 2015 (Contd..15)
Products under Development by Companies, H2 2015 (Contd..16)
Products under Development by Companies, H2 2015 (Contd..17)
Products under Development by Companies, H2 2015 (Contd..18)
Products under Development by Companies, H2 2015 (Contd..19)
Products under Development by Companies, H2 2015 (Contd..20)
Products under Development by Companies, H2 2015 (Contd..21)
Products under Development by Companies, H2 2015 (Contd..22)
Products under Development by Companies, H2 2015 (Contd..23)
Products under Development by Companies, H2 2015 (Contd..24)
Products under Development by Companies, H2 2015 (Contd..25)
Products under Development by Companies, H2 2015 (Contd..26)
Products under Development by Companies, H2 2015 (Contd..27)
Products under Development by Companies, H2 2015 (Contd..28)
Products under Development by Companies, H2 2015 (Contd..29)
Products under Development by Companies, H2 2015 (Contd..30)
Products under Development by Companies, H2 2015 (Contd..31)
Products under Development by Companies, H2 2015 (Contd..32)
Products under Development by Companies, H2 2015 (Contd..33)
Products under Development by Companies, H2 2015 (Contd..34)
Products under Development by Companies, H2 2015 (Contd..35)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H2 2015
Non-Small Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015
Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Ability Pharma, SL, H2 2015
Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Limited, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Altimmune, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corporation, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Amgen Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by AndroScience Corporation, H2 2015
Non-Small Cell Lung Cancer - Pipeline by APO-T B.V., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Arch Biopartners, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Arog Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by ArQule, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H2 2015
Non-Small Cell Lung Cancer - Pipeline by ATLAB Pharma SAS, H2 2015
Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Axelar AB, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H2 2015
Non-Small Cell Lung Cancer - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Benitec Biopharma Limited, H2 2015
Non-Small Cell Lung Cancer - Pipeline by BerGenBio AS, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Beta Pharma, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by BIND Therapeutics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Bio-Path Holdings, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by BIOCAD, H2 2015
Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H2 2015
Non-Small Cell Lung Cancer - Pipeline by BioLineRx, Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Bionovis SA, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Biothera, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Calithera Biosciences, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by CanBas Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by CASI Pharmaceuticals Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by cCAM Biotherapeutics Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Celgene Corporation, H2 2015
Non-Small Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Cellceutix Corporation, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Cellectis S.A., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Cellmid Limited, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Celltrion, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Cellular Biomedicine Group, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Clovis Oncology, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Corcept Therapeutics Incorporated, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by CTI BioPharma Corp., H2 2015
Non-Small Cell Lung Cancer - Pipeline by CureFAKtor Pharmaceuticals, LLC, H2 2015
Non-Small Cell Lung Cancer - Pipeline by CureVac GmbH, H2 2015
Non-Small Cell Lung Cancer - Pipeline by CytRx Corporation, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Non-Small Cell Lung Cancer - Pipeline by DanDrit Biotech A/S, H2 2015
Non-Small Cell Lung Cancer - Pipeline by DEKK-TEC, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Denovo Biopharma, LLC, H2 2015
Non-Small Cell Lung Cancer - Pipeline by DiNonA Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Domainex Limited, H2 2015
Non-Small Cell Lung Cancer - Pipeline by DormaTarg, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Eagle Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by EirGenix Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Eisai Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Endocyte, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by EnGeneIC Ltd, H2 2015
Non-Small Cell Lung Cancer - Pipeline by EntreChem, S.L., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Eudendron S.r.l., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Exelixis, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Fujifilm Corporation, H2 2015
Non-Small Cell Lung Cancer - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Genelux Corporation, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Genentech, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Genmab A/S, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Genosco, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Genzyme Corporation, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Gilead Sciences, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Globeimmune, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by GlycaNova Norway AS, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Glycotope GmbH, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Golden Biotechnology Corp., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Gradalis Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Halozyme Therapeutics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Heat Biologics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by HEC Pharm Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Helix BioPharma Corp., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Hospira, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Humanetics Corporation, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Hutchison MediPharma Limited, H2 2015
Non-Small Cell Lung Cancer - Pipeline by iCeutica, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Ignyta, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Immune Design Corp., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Immune Pharmaceuticals Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by ImmunGene, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by ImmunoFrontier, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by ImmunoGen, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Immunome Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Immunomedics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Incanthera Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Incuron, LLC, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Incyte Corporation, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Inflection Biosciences Limited, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Intezyne, Inc, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Inventiva SAS, H2 2015
Non-Small Cell Lung Cancer - Pipeline by IO Biotech ApS, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Io Therapeutics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Johnson & Johnson, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Juno Therapeutics Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Kadmon Corporation, LLC, H2 2015
Non-Small Cell Lung Cancer - Pipeline by KAEL-GemVax Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Komipharm International Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Kura Oncology, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Loxo Oncology, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Mabion SA, H2 2015
Non-Small Cell Lung Cancer - Pipeline by MacroGenics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by MedImmune, LLC, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Merck & Co., Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Merck KGaA, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Mersana Therapeutics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Mirati Therapeutics Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Modulation Therapeutics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by MolMed S.p.A., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Morphotek, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Multimmune GmbH, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Mycenax Biotech Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Natco Pharma Limited, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Nektar Therapeutics, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Nemucore Medical Innovations, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by NeoPharm Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Netris Pharma S.A.S., H2 2015
Non-Small Cell Lung Cancer - Pipeline by NewLink Genetics Corporation, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Nimbus Therapeutics, LLC, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Novartis AG, H2 2015
Non-Small Cell Lung Cancer - Pipeline by NuCana BioMed Limited, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Oncobiologics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Oncology Research International Limited, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Oncolytics Biotech Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Oncothyreon Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Onxeo SA, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Optimum Therapeutics, LLC, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Oscotec Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by OSE Pharma SA, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Panacea Biotec Limited, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Pfizer Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Pharma Mar, S.A., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Philogen S.p.A., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Pique Therapeutics, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Plexxikon Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Puma Biotechnology, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Purdue Pharma L.P., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Qu Biologics Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Reata Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Recombio S.L, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Samyang Holdings Corporation, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Sanofi, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Sapvax, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Sareum Holdings Plc, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Shionogi & Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by SignPath Pharma Inc, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Sirnaomics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Sotio a.s., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by STELIS Biopharma Pvt. Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Stemline Therapeutics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by SuviCa Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Symphogen A/S, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by TC BioPharm Limited, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Tolero Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Transgene SA, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Ultimovacs AS, H2 2015
Non-Small Cell Lung Cancer - Pipeline by VasGene Therapeutics, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Vaxon Biotech, H2 2015
Non-Small Cell Lung Cancer - Pipeline by Verastem, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Verlyx Pharma Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015
Non-Small Cell Lung Cancer - Pipeline by VG Life Sciences, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Vichem Chemie Research Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Viralytics Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by XBiotech USA, Inc., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Zhejiang BetaPharma Co., Ltd., H2 2015
Non-Small Cell Lung Cancer - Pipeline by Zyngenia, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Non-Small Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H2 2015 1375
Non-Small Cell Lung Cancer - Dormant Projects, H2 2015 1979
Non-Small Cell Lung Cancer - Dormant Projects (Contd..1), H2 2015 1980
Non-Small Cell Lung Cancer - Dormant Projects (Contd..2), H2 2015 1981
Non-Small Cell Lung Cancer - Dormant Projects (Contd..3), H2 2015 1982
Non-Small Cell Lung Cancer - Dormant Projects (Contd..4), H2 2015 1983
Non-Small Cell Lung Cancer - Dormant Projects (Contd..5), H2 2015 1984
Non-Small Cell Lung Cancer - Dormant Projects (Contd..6), H2 2015 1985
Non-Small Cell Lung Cancer - Dormant Projects (Contd..7), H2 2015 1986
Non-Small Cell Lung Cancer - Dormant Projects (Contd..8), H2 2015 1987
Non-Small Cell Lung Cancer - Dormant Projects (Contd..9), H2 2015 1988
Non-Small Cell Lung Cancer - Dormant Projects (Contd..10), H2 2015 1989
Non-Small Cell Lung Cancer - Dormant Projects (Contd..11), H2 2015 1990
Non-Small Cell Lung Cancer - Dormant Projects (Contd..12), H2 2015 1991
Non-Small Cell Lung Cancer - Dormant Projects (Contd..13), H2 2015 1992
Non-Small Cell Lung Cancer - Dormant Projects (Contd..14), H2 2015 1993
Non-Small Cell Lung Cancer - Dormant Projects (Contd..15), H2 2015 1994
Non-Small Cell Lung Cancer - Dormant Projects (Contd..16), H2 2015 1995
Non-Small Cell Lung Cancer - Dormant Projects (Contd..17), H2 2015 1996
Non-Small Cell Lung Cancer - Dormant Projects (Contd..18), H2 2015 1997
Non-Small Cell Lung Cancer - Dormant Projects (Contd..19), H2 2015 1998
Non-Small Cell Lung Cancer - Dormant Projects (Contd..20), H2 2015 1999
Non-Small Cell Lung Cancer - Dormant Projects (Contd..21), H2 2015 2000
Non-Small Cell Lung Cancer - Dormant Projects (Contd..22), H2 2015 2001
Non-Small Cell Lung Cancer - Dormant Projects (Contd..23), H2 2015 2002
Non-Small Cell Lung Cancer - Dormant Projects (Contd..24), H2 2015 2003
Non-Small Cell Lung Cancer - Dormant Projects (Contd..25), H2 2015 2004
Non-Small Cell Lung Cancer - Dormant Projects (Contd..26), H2 2015 2005
Non-Small Cell Lung Cancer - Discontinued Products, H2 2015 2006
Non-Small Cell Lung Cancer - Discontinued Products (Contd..1), H2 2015 2007
Non-Small Cell Lung Cancer - Discontinued Products (Contd..2), H2 2015 2008
Non-Small Cell Lung Cancer - Discontinued Products (Contd..3), H2 2015 2009
Non-Small Cell Lung Cancer - Discontinued Products (Contd..4), H2 2015 2010
Non-Small Cell Lung Cancer - Discontinued Products (Contd..5), H2 2015 2011
Non-Small Cell Lung Cancer - Discontinued Products (Contd..6), H2 2015 2012
Non-Small Cell Lung Cancer - Discontinued Products (Contd..7), H2 2015 2013
Non-Small Cell Lung Cancer - Discontinued Products (Contd..8), H2 2015 2014
Non-Small Cell Lung Cancer - Discontinued Products (Contd..9), H2 2015 2015
Non-Small Cell Lung Cancer - Discontinued Products (Contd..10), H2 2015 2016

LIST OF FIGURES

Number of Products under Development for Non-Small Cell Lung Cancer, H2 2015
Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc.
Ability Pharma, SL
ACEA Biosciences, Inc.
Adaptimmune Limited
Advanced Cancer Therapeutics
Advenchen Laboratories, LLC
Aeolus Pharmaceuticals, Inc.
Altimmune, Inc.
Altor BioScience Corporation
Amgen Inc.
Andarix Pharmaceuticals, Inc.
AndroScience Corporation
APO-T B.V.
Aptose Biosciences Inc.
Arch Biopartners, Inc.
Ariad Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
ArQule, Inc.
Array BioPharma Inc.
Arrien Pharmaceuticals, LLC
Ascenta Therapeutics, Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
ATLAB Pharma SAS
AVEO Pharmaceuticals, Inc.
Axelar AB
Azaya Therapeutics, Inc.
Basilea Pharmaceutica AG
Bavarian Nordic A/S
Bayer AG
BeiGene(Beijing) Co.,Ltd
Benitec Biopharma Limited
BerGenBio AS
Beta Pharma, Inc.
BIND Therapeutics, Inc.
Bio-Path Holdings, Inc.
BIOCAD
BioCancell Ltd
BioLineRx, Ltd.
Bionovis SA
Biothera, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
CanBas Co., Ltd.
CASI Pharmaceuticals Inc.
cCAM Biotherapeutics Ltd.
Celgene Corporation
CellAct Pharma GmbH
Cellceutix Corporation
Celldex Therapeutics, Inc.
Cellectar Biosciences, Inc.
Cellectis S.A.
Cellmid Limited
Celltrion, Inc.
Cellular Biomedicine Group, Inc.
Chipscreen Biosciences Ltd
Chugai Pharmaceutical Co., Ltd.
Clovis Oncology, Inc.
Corcept Therapeutics Incorporated
Cornerstone Pharmaceuticals, Inc.
Critical Outcome Technologies Inc.
CTI BioPharma Corp.
CureFAKtor Pharmaceuticals, LLC
CureVac GmbH
CytRx Corporation
Daiichi Sankyo Company, Limited
DanDrit Biotech A/S
DEKK-TEC, Inc.
Denovo Biopharma, LLC
DiNonA Inc.
Domainex Limited
DormaTarg, Inc.
Double Bond Pharmaceutical International AB
Dr. Reddy's Laboratories Limited
Eagle Pharmaceuticals, Inc.
EirGenix Inc.
Eisai Co., Ltd.
Eleison Pharmaceuticals LLC
Eli Lilly and Company
Endocyte, Inc.
EnGeneIC Ltd
EntreChem, S.L.
Epirus Biopharmaceuticals, Inc.
Eudendron S.r.l.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Fujifilm Corporation
G&E Herbal Biotechnology Co., Ltd.
Ganymed Pharmaceuticals AG
Genelux Corporation
Genentech, Inc.
Genmab A/S
Genor BioPharma Co., Ltd.
Genosco
Genzyme Corporation
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Globeimmune, Inc.
GlycaNova Norway AS
Glycotope GmbH
Golden Biotechnology Corp.
Gradalis Inc.
Halozyme Therapeutics, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Heat Biologics, Inc.
HEC Pharm Co., Ltd.
Helix BioPharma Corp.
Horizon Pharma Plc
Hospira, Inc.
Humanetics Corporation
Hutchison MediPharma Limited
iCeutica, Inc.
Ignyta, Inc.
Immune Design Corp.
Immune Pharmaceuticals Inc.
ImmunGene, Inc.
ImmunoFrontier, Inc.
ImmunoGen, Inc.
Immunome Inc.
Immunomedics, Inc.
Incanthera Ltd.
Incuron, LLC
Incyte Corporation
Inflection Biosciences Limited
Intezyne, Inc
Inventiva SAS
IO Biotech ApS
Io Therapeutics, Inc.
Jeil Pharmaceutical Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Kanion Pharmaceutical Co., Ltd.
Johnson & Johnson
Juno Therapeutics Inc.
Kadmon Corporation, LLC
KAEL-GemVax Co., Ltd.
Kolltan Pharmaceuticals, Inc.
Komipharm International Co., Ltd.
Kura Oncology, Inc.
Kyowa Hakko Kirin Co., Ltd.
Les Laboratoires Servier SAS
Loxo Oncology, Inc.
Mabion SA
MacroGenics, Inc.
Mebiopharm Co., Ltd.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Mersana Therapeutics, Inc.
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Mirna Therapeutics, Inc.
Modulation Therapeutics, Inc.
MolMed S.p.A.
Morphotek, Inc.
Multimmune GmbH
Mycenax Biotech Inc.
NanoCarrier Co., Ltd.
Natco Pharma Limited
Nektar Therapeutics
Nemucore Medical Innovations, Inc.
NeoPharm Co., Ltd.
Netris Pharma S.A.S.
NewLink Genetics Corporation
Nimbus Therapeutics, LLC
Northwest Biotherapeutics, Inc.
Novartis AG
NuCana BioMed Limited
Omnitura Therapeutics Inc.
Oncobiologics, Inc.
Oncogenex Pharmaceuticals, Inc.
Oncology Research International Limited
Oncolytics Biotech Inc.
OncoMed Pharmaceuticals, Inc.
Oncothyreon Inc.
Ono Pharmaceutical Co., Ltd.
Onxeo SA
Onyx Pharmaceuticals, Inc.
Optimum Therapeutics, LLC
Oscotec Inc.
OSE Pharma SA
Oxford BioTherapeutics Ltd
Panacea Biotec Limited
Peregrine Pharmaceuticals, Inc.
Pfizer Inc.
Pharma Mar, S.A.
Philogen S.p.A.
Pique Therapeutics
Plexxikon Inc.
Polaris Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
Puma Biotechnology, Inc.
Purdue Pharma L.P.
Qu Biologics Inc.
Reata Pharmaceuticals, Inc.
Recombio S.L
Rexahn Pharmaceuticals, Inc.
Samyang Holdings Corporation
Sanofi
Sapvax
Sareum Holdings Plc
Shanghai Henlius Biotech Co., Ltd.
Shenzen SiBiono GeneTech Co., Ltd
Shionogi & Co., Ltd.
SignPath Pharma Inc
Sirnaomics, Inc.
Sorrento Therapeutics, Inc.
Sotio a.s.
Spectrum Pharmaceuticals, Inc.
Sphaera Pharma Pvt. Ltd.
STELIS Biopharma Pvt. Ltd.
Stemline Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
SuviCa Inc.
Symphogen A/S
Syndax Pharmaceuticals, Inc.
Sy
Skip to top


Ask Your Question

Non-Small Cell Lung Cancer - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: